HRC Corporate Equality Index 2021 Scores by State
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Jefferies Financial Group Inc. 2019 Investor Meeting
Jefferies Financial Group Inc. 2019 Investor Meeting Wednesday, October 16, 2019 Presentations and Q&A Note on Forward Looking Statements Certain statements contained herein may constitute "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and/or the Private Securities Litigation Reform Act of 1995, regarding Jefferies Financial Group Inc., Jefferies Group LLC, Spectrum Brands Holdings, Inc. and Global Brokerage, Inc., and their respective subsidiaries. These forward-looking statements reflect the respective issuer’s current views relating to, among other things, future revenues, earnings, operations, and other financial results, and may include statements of future performance, plans, and objectives. Forward-looking statements may also include statements pertaining to an issuer’s strategies for the future development of its business and products. These forward- looking statements are not historical facts and are based on the respective issuer’s management expectations, estimates, projections, beliefs and certain other assumptions, many of which, by their nature, are inherently uncertain and beyond management’s control. It is possible that the actual results may differ, possibly materially, from the anticipated results indicated in these forward-looking statements. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict including, without limitation, the cautionary statements and risks set forth in the respective issuer’s Annual and Quarterly Reports and other reports or documents filed with, or furnished to, the SEC from time to time, which are accessible on the SEC website at sec.gov. -
Master Thesis Master's Programme in Industrial Management and Innovation, 120 Credits
Master Thesis Master's Programme in Industrial Management and Innovation, 120 credits Capturing Business Model Innovation Driven by the Emergence of New Technologies in Established Firms A Case Study at Siemens Healthineers Thesis in Industrial Innovation Management, 30 credits Halmstad 2018-06-16 Emma Bäckman, Josefin Ellmarker HALMSTAD UNIVERSITY Abstract Background: It is argued that the emergence of new technologies and the digitalization can improve the healthcare, make it more efficient, personalized and available for everyone. The healthcare has already begun to become more digitized and there is no doubt that this trend will continue. Moreover, it is argued that AI will have a major impact on the MedTech and healthcare industry. Problem discussion: To stay competitive it has been concluded that firms must update and rethink their business models constantly thus, to undertake business model innovation. This applies specially to established firms that have been successful with the same business model for a long time. Despite the fact that the existing literature addresses the importance of business model innovation, very little attention has been drawn to how to actually achieve this change. Purpose: The purpose of this study is to explore how business models in established firms within the MedTech industry develops over time due to the emergence of new technologies. More specifically, we focus on how artificial intelligence is influencing and will influence the business models in the MedTech industry. Methodology: This study has been performed through a single case study at Siemens Healthineers. The primary data has been gathered through four meetings with people with expertise in the field of artificial intelligence as well as the MedTech and healthcare industry. -
Medical Additive Manufacturing/ 3D Printing Annual Report 2018 Improving Public Health
Medical Additive Manufacturing/ 3D Printing Annual Report 2018 Improving Public Health Each year, healthcare needs and costs grow due to an aging population, the rise in chronic diseases, and more. In fact, global healthcare spending is projected to reach nearly $9 trillion by 20201. To address this, practitioners in the healthcare industry continue to look for innovations that can provide quality care to patients at a reasonable cost. But they can’t do it alone. Today, the manufacturing industry is an important partner, with one particularly bright opportunity focused on Medical Additive Manufacturing/3D Printing (AM3DP). From anatomical models to early bioprinting applications, the use of AM3DP is providing benefits for patients and physicians/institutions including: ■ Better patient outcomes ■ Less time in the operating room ■ Reduced costs In 2017, as outlined in this Annual Report, collaboration between hospitals, device manufacturers, U.S. Food and Drug Administration (FDA), and partners such as SME, led to extraordinary strides in identifying industry trends, opportunities, challenges and solutions. These partnerships drive efficiency through best practice sharing as well as accelerate innovation for applications such as bioprinting and tissue fabrication. They also lay the groundwork for 3D printing of organs and scaling up production of tissues which are still decades away. With millions of patients already directly impacted by the technology, this momentum continues into 2018 and beyond where AM3DP will continue to positively impact public health and drive strong business results. This 2017 Annual Report covers: COVER: Justin Ryan holds a pediatric heart model 3D-printed at the ■ Industry Overview Phoenix Children’s Hospital Cardiac 3D Print Lab. -
U.S. Corporate Scores 2018
01 DISCLOSURE INSIGHT ACTION U.S. CORPORATE SCORES 2018 02 CORPORATE DISCLOSURE TO INVESTORS IN NORTH AMERICA 124 9 28 510 63 192 CONTENTS 03 04 CDP scoring methodology 2018 06 The A-List: North America 08 Corporate scores 34 Appendix I: CDP Activity classification system (cdp-acs) 40 Appendix II: Investor Members and Signatories 46 Appendix III: CDP Supply Chain Members Important Notice The contents of this report may be used by anyone providing acknowledgment is given to CDP. This does not represent a license to repackage or resell any of the data reported to CDP or the contributing authors and presented in this report. If you intend to repackage or resell any of the contents of this report, you need to obtain express permission from CDP before doing so. CDP has prepared the data and analysis in this report based on responses to the CDP 2018 information request. No representation or warranty (express or implied) is given by CDP as to the accuracy or completeness of the information and opinions contained in this report. You should not act upon the information contained in this publication without obtaining specific professional advice. To the extent permitted by law, CDP does not accept or assume any liability, responsibility or duty of care for any consequences of you or anyone else acting, or refraining to act, in reliance on the information contained in this report or for any decision based on it. All information and views expressed herein by CDP are based on their judgment at the time of this report and are subject to change without notice due to economic, political, industry and firm-specific factors. -
Healthcare & Life Sciences Group
HEALTHCARE & LIFE SCIENCES GROUP 2 1 Healthcare and life sciences clients have long turned to S&C for help succeeding in today’s rapidly changing business environment. Large and mid-size, public and private, throughout their lifecycles, these companies rely on our multi-disciplinary, global team to address their most complex legal and business challenges and reach their strategic goals. Sector expertise: We offer unrivaled OUR CLIENTS GET… knowledge of the healthcare and life sciences industries, our clients’ businesses and the sector-specific competitive pressures bearing down on them. Sullivan & Cromwell’s Healthcare and Life Sciences Group has negotiated complex transactions and resolved high-stakes disputes for almost three decades. Today, it possesses an unparalleled grasp of these sectors and a practical understanding of the commercial realities underlying them. We position our clients to succeed through it all. The Firm represents international clients in the following healthcare sectors: Pharmaceuticals and Life Sciences Medtech Health Insurers Healthcare Services 2 Legal expertise: Clients come to us An integrated, global team: for the high-quality counsel and hands-on We’re a core group of dedicated healthcare representation we offer across multiple advisers across our 13 offices on four legal specialties, to successfully execute continents with a strong track record of their most important deals and resolve the sector’s most significant transactions critical disputes. We can execute any type and litigation matters, supported by all of transaction in any economic climate or the resources of an integrated, global firm. geographic region. Our experience in this We’re grateful to our clients for trusting sector includes: us with their future, and we’ll continue to help them position themselves for growth M&A and success in this exciting and ever- Corporate finance changing industry. -
LAZARD GROUP LLC (Exact Name of Registrant As Specified in Its Charter)
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2008 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 333-126751 (Commission File Number) LAZARD GROUP LLC (Exact name of registrant as specified in its charter) Delaware 51-0278097 (State or Other Jurisdiction of Incorporation (I.R.S. Employer Identification No.) or Organization) 30 Rockefeller Plaza New York, NY 10020 (Address of principal executive offices) Registrant’s telephone number: (212) 632-6000 Securities Registered Pursuant to Section 12(b) of the Act: None Securities Registered Pursuant to Section 12(g) of the Act: None Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of Registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. -
NASDAQ Stock Market
Nasdaq Stock Market Friday, December 28, 2018 Name Symbol Close 1st Constitution Bancorp FCCY 19.75 1st Source SRCE 40.25 2U TWOU 48.31 21st Century Fox Cl A FOXA 47.97 21st Century Fox Cl B FOX 47.62 21Vianet Group ADR VNET 8.63 51job ADR JOBS 61.7 111 ADR YI 6.05 360 Finance ADR QFIN 15.74 1347 Property Insurance Holdings PIH 4.05 1-800-FLOWERS.COM Cl A FLWS 11.92 AAON AAON 34.85 Abiomed ABMD 318.17 Acacia Communications ACIA 37.69 Acacia Research - Acacia ACTG 3 Technologies Acadia Healthcare ACHC 25.56 ACADIA Pharmaceuticals ACAD 15.65 Acceleron Pharma XLRN 44.13 Access National ANCX 21.31 Accuray ARAY 3.45 AcelRx Pharmaceuticals ACRX 2.34 Aceto ACET 0.82 Achaogen AKAO 1.31 Achillion Pharmaceuticals ACHN 1.48 AC Immune ACIU 9.78 ACI Worldwide ACIW 27.25 Aclaris Therapeutics ACRS 7.31 ACM Research Cl A ACMR 10.47 Acorda Therapeutics ACOR 14.98 Activision Blizzard ATVI 46.8 Adamas Pharmaceuticals ADMS 8.45 Adaptimmune Therapeutics ADR ADAP 5.15 Addus HomeCare ADUS 67.27 ADDvantage Technologies Group AEY 1.43 Adobe ADBE 223.13 Adtran ADTN 10.82 Aduro Biotech ADRO 2.65 Advanced Emissions Solutions ADES 10.07 Advanced Energy Industries AEIS 42.71 Advanced Micro Devices AMD 17.82 Advaxis ADXS 0.19 Adverum Biotechnologies ADVM 3.2 Aegion AEGN 16.24 Aeglea BioTherapeutics AGLE 7.67 Aemetis AMTX 0.57 Aerie Pharmaceuticals AERI 35.52 AeroVironment AVAV 67.57 Aevi Genomic Medicine GNMX 0.67 Affimed AFMD 3.11 Agile Therapeutics AGRX 0.61 Agilysys AGYS 14.59 Agios Pharmaceuticals AGIO 45.3 AGNC Investment AGNC 17.73 AgroFresh Solutions AGFS 3.85 -
Market Cap Close ADV
Market Cap Close ADV 1598 67th Pctl $745,214,477.91 $23.96 225,966.94 801 33rd Pctl $199,581,478.89 $10.09 53,054.83 2399 Listing_ Revised Ticker_Symbol Security_Name Exchange Effective_Date Mkt Cap Close ADV Stratum Stratum AAC AAC Holdings, Inc. N 20160906 M M M M-M-M M-M-M Altisource Asset Management AAMC Corp A 20160906 L M L L-M-L L-M-L AAN Aarons Inc N 20160906 H H H H-H-H H-H-H AAV Advantage Oil & Gas Ltd N 20160906 H L M H-L-M H-M-M AB Alliance Bernstein Holding L P N 20160906 H M M H-M-M H-M-M ABG Asbury Automotive Group Inc N 20160906 H H H H-H-H H-H-H ABM ABM Industries Inc. N 20160906 H H H H-H-H H-H-H AC Associated Capital Group, Inc. N 20160906 H H L H-H-L H-H-L ACCO ACCO Brand Corp. N 20160906 H L H H-L-H H-L-H ACU Acme United A 20160906 L M L L-M-L L-M-L ACY AeroCentury Corp A 20160906 L L L L-L-L L-L-L ADK Adcare Health System A 20160906 L L L L-L-L L-L-L ADPT Adeptus Health Inc. N 20160906 M H H M-H-H M-H-H AE Adams Res Energy Inc A 20160906 L H L L-H-L L-H-L American Equity Inv Life Hldg AEL Co N 20160906 H M H H-M-H H-M-H AF Astoria Financial Corporation N 20160906 H M H H-M-H H-M-H AGM Fed Agricul Mtg Clc Non Voting N 20160906 M H M M-H-M M-H-M AGM A Fed Agricultural Mtg Cla Voting N 20160906 L H L L-H-L L-H-L AGRO Adecoagro S A N 20160906 H L H H-L-H H-L-H AGX Argan Inc N 20160906 M H M M-H-M M-H-M AHC A H Belo Corp N 20160906 L L L L-L-L L-L-L ASPEN Insurance Holding AHL Limited N 20160906 H H H H-H-H H-H-H AHS AMN Healthcare Services Inc. -
Spare the Air Employer Program Members List Last Updated: March
Spare the Air Employer Program Members 1000 Journals Project Alameda County - Health Care for the 2Plus2 Partners Homeless Program 3Degrees Alameda Free Library 49 Square Catering Alameda Hospital 511 Contra Costa - Pleasant Hill Alameda Natural Grocery 511 Contra Costa - San Pablo Albion Power Company, Inc. 511 Regional Rideshare Program Aldea, Inc. 5HT Inc. dba EarthBaby Alexa Internet 7 Flags Car Wash - Vacaville All American Containers 88hvac All Covered A. Maciel Printing Allergy Medical Group Of S F A A&D Christopher Ranch Alliance Credit Union A1 Sun Inc Allied Waste Services -- SCCO Division A9.com 4915 AB & I Allison & Partners ABA Staffing, Inc. Almaden Press Abbot Vascular Structural Heart Aloft Cupertino Absolute Center Alpha Omega Academy of Chinese Culture & Health Alta Bates/Summit Medical Center Acadia Veterinary Clinic Altera Corporation Acclaim Print & Copy Centers ALTRANS TMA, Inc Acclarent, Inc. Alum Rock Library Accretive Solutions - Mountain View Amcor Packaging Distribution ACEQ Investment Group AMEC Acterra AMEC E& I Actify, Inc. Amelias Antics Actiontec Electronics American Bookbinders Museum Addis Creson American International (Group) Companies Adler & Colvin American Lung Association in California - Adobe Lumber Oakland Advance Design Consultants, Inc. American Lung Association in California - Advanced Hyperbaric Recovery of Marin Santa Rosa Advance Orthopaedics AMFASOFT CORPORATION Advantage Sales & Marketing Amgen Advent Software, Inc. Amorim Cork America Aeronet Communications Crop Amphenol Advanced Sensors Affinture Amtrak Affordable Housing Associates Amy's Kitchen Affordable Treasures Anasa Yoga, LLC Agilent Anastasia Nicole Consulting AGS, Inc. Anca Vladescu, DDS Air Products and Chemicals, Inc. Anchor QEA Air Systems Inc. Anderson Brulé Architects, Inc. Akira Andrades Automotive Alameda County Andrew B. -
EMS Counterparty Spreadsheet Master
1 ECHO MONITORING SOLUTIONS COUNTERPARTY RATINGS REPORT Updated as of October 24, 2012 S&P Moody's Fitch DBRS Counterparty LT Local Sr. Unsecured Sr. Unsecured Sr. Unsecured ABN AMRO Bank N.V. A+ A2 A+ Agfirst Farm Credit Bank AA- AIG Financial Products Corp A- WR Aig-fp Matched Funding A- Baa1 Allied Irish Banks PLC BB Ba3 BBB BBBL AMBAC Assurance Corporation NR WR NR American International Group Inc. (AIG) A- Baa1 BBB American National Bank and Trust Co. of Chicago (see JP Morgan Chase Bank) Assured Guaranty Ltd. (U.S.) A- Assured Guaranty Municipal Corp. AA- Aa3 *- NR Australia and New Zealand Banking Group Limited AA- Aa2 AA- AA Banco Bilbao Vizcaya Argentaria, S.A. BBB- Baa3 *- BBB+ A Banco de Chile A+ NR NR Banco Santander SA (Spain) BBB (P)Baa2 *- BBB+ A Banco Santander Chile A Aa3 *- A+ Bank of America Corporation A- Baa2 A A Bank of America, NA AA3AAH Bank of New York Mellon Trust Co NA/The AA- AA Bank of North Dakota/The AA- A1 Bank of Scotland PLC (London) A A2 A AAL Bank of the West/San Francisco CA A Bank Millennium SA BBpi Bank of Montreal A+ Aa2 AA- AA Bank of New York Mellon/The (U.S.) AA- Aa1 AA- AA Bank of Nova Scotia (Canada) AA- Aa1 AA- AA Bank of Tokyo-Mitsubish UFJ Ltd A+ Aa3 A- A Bank One( See JP Morgan Chase Bank) Bankers Trust Company (see Deutsche Bank AG) Banknorth, NA (See TD Bank NA) Barclays Bank PLC A+ A2 A AA BASF SE A+ A1 A+ Bayerische Hypo- und Vereinsbank AG (See UniCredit Bank AG) Bayerische Landesbank (parent) NR Baa1 A+ Bear Stearns Capital Markets Inc (See JP Morgan Chase Bank) NR NR NR Bear Stearns Companies, Inc. -
Fueling Economic Growth
The Business Case For MINORITY BUSINESS ENTERPRISES Fueling Economic Growth 1 THE FUTURE MAJORITY 120 million strong and increasing by 2.3 million per year, multicultural populations are the growth engine of the future in the U.S. Hispanics, African-Americans, Asian- Americans, and all other multiculturals already make up 38% of the U.S. population, with Census projections showing that multicultural populations will become a numeric majority by 2044. 2 .. TOC Advancing Business Connections That Count Contents Our Goals & Call To Action ....................................................................................... 5 Our Mission ............................................................................................................. 7 NMSDC By The Numbers ......................................................................................... 8 National Corporate Members ....................................................................................14 National Affiliates .................................................................................................... 18 Growth Trends - The Emerging Minority Marketplace ....................................................... 20 Economic Impact ...................................................................................................... 21 Minority Purchasing Power .......................................................................................... 24 U.S. Population Growth ............................................................................................ -
2020 Annual Report
CAPABILITIES INVESTMENT BANKING MARKETS RESEARCH INVESTMENT MANAGEMENT LOCATIONS U.S. INTERNATIONAL ATLANTA BELFAST BOSTON BERLIN CHICAGO FRANKFURT CLEVELAND GRAZ DALLAS HONG KONG REPORT 2020 ANNUAL DETROIT LEIPZIG HOUSTON LONDON INDIANAPOLIS LUXEMBOURG LOS ANGELES MALTA MINNEAPOLIS MUNICH NEW YORK ZURICH ORLANDO SAN FRANCISCO STAMFORD WASHINGTON, DC ANNUAL REPORT ©2021 COWEN, INC. ALL RIGHTS RESERVED. COWEN.COM COWEN INC. COWEN COWENRESEARCH 2020COWEN.COM COWEN INC. COWEN COWENRESEARCH LETTER FROM THE CHAIR & CEO 2020 was a challenging year, to put it mildly. But in the face of adversity and disruption, the Cowen team rose to the occasion, helping our clients outperform and delivering the best operating and financial results on record.2020 was the first year we cracked the $1 billion mark in revenues, generating over $1.5 billion. We also recorded our highest ever economic operating income with over $330 million. These impressive milestones did not happen overnight — they were years in the making. The direct result of careful strategic planning and targeted investment. But above all else, they are a testament to the hard work and dedication of the Cowen team. A GROWING PLATFORM — 2020 REVENUE MIX* DEAR SHAREHOLDERS, PARTNERS, COLLEAGUES AND FRIENDS: INVESTMENT BANKINGMuch47% has been written about 2020 and its BROKERAGE painful42% experiences – the disruption and divisions, challenges and chaos. It is the year MANAGEMENT FEE 4% that will forever be the watershed for the rest INCENTIVE INCOME 5% $1.6B of our lives. A year when people around the INVESTMENT INCOME 2% world—individually and collectively—experienced OTHER 0% something that was previously unthinkable—all at the same time.